Sera Prognostics (SERA)
NASDAQ:SERA
Want to see SERA full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong strategic progress on commercialization, payer engagement, media awareness, scientific publications and a clear plan to reduce operating expense that together support a multi-year commercial opportunity. However, near-term financials remain weak — Q1 revenue fell to $14k (down ~63% YoY), a continuing net loss (~$8.4M) and management expects 2026 revenue to be modest and uneven while payer coverage and broader adoption timelines play out. Given meaningful operational and evidence milestones but limited near-term revenue visibility, the tone is cautiously constructive but balanced by financial and timing risks.Company Guidance
Strong cash runway and cost-reduction plan
Cash, cash equivalents and available-for-sale securities of $86.8 million at March 31, 2026; company expects to reduce base operating expenses by nearly $10 million annually, extending runway and management believes cash is sufficient to fund operations through 2029.
Commercial and payer engagement momentum
Launched a third partnership program in Q1 (now 2 live programs plus the new one) with plans to stand up ~one program per quarter; engaged in active discussions with 13 payers across 15 states (up from 10 payers in 13 states prior quarter), pursuing a focused market approach to drive implementation and pull-through.
Awareness and media traction
Broad media and outreach efforts including a SHE MD podcast episode featuring Hailey Bieber that surpassed 0.5 million views; additional targeted podcast and media appearances planned to drive patient and provider awareness and advocacy.
Scientific publications and evidence building
Full PRIME study published; European expert commentary published in the Journal of Maternal Fetal and Neonatal Medicine (March); PREPARE survey accepted for publication; multiple PRIME sub-analyses planned in 2026 including a health economic study and Medicaid outcomes to strengthen clinical and economic case for adoption.
Regulatory progress in Europe
On track for a midyear CE Marking dossier submission and constructive engagement with European regulators and clinical stakeholders, advancing commercialization readiness in Europe.
Strategic shift to commercialization
Company realigned resources from R&D/clinical operations toward commercialization, payer engagement and market access; R&D expense declined to $3.0 million in Q1 2026 (from $3.3 million in Q1 2025, ~9.1% decrease), reflecting transition toward revenue-driving activities.
SERA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SERA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $1.81 | $1.92 | +6.08% |
Mar 18, 2026 | $1.91 | $1.79 | -6.28% |
Nov 13, 2025 | $2.95 | $2.96 | +0.34% |
Aug 06, 2025 | $2.75 | $2.60 | -5.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sera Prognostics (SERA) report earnings?
Sera Prognostics (SERA) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Sera Prognostics (SERA) earnings time?
Sera Prognostics (SERA) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SERA EPS forecast?
SERA EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.